Low levels are often associated with fatigue and slower recovery
Semaglutide was associated with gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) which were of mild to moderate severity, short duration, and resolved without treatment discontinuation ( Notably, a recent systematic review showed that compared to other semaglutide doses and GLP-1 RAs, 2.4 mg semaglutide had the greatest effect on weight reduction, controlling glucose level, and reducing BP
This substance is responsible for many of the unpleasant symptoms of a hangover, including headaches, nausea, and fatigue
Semaglutide works by helping the patient feel full on less food and slowing the passage of food through the digestive tract
The new research published in April 2026 showed improved blood pressure and cholesterol markers in participants, but a dedicated cardiovascular outcomes trial with hard endpoints is still in progress